Carboplatin (NSC 241240)

For research use only.

Catalog No.S1215 Synonyms: JM-8, CBDCA

69 publications

Carboplatin (NSC 241240) Chemical Structure

CAS No. 41575-94-4

Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Size Price Stock Quantity  
EUR 75 In stock
EUR 105 In stock
EUR 164 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Carboplatin (NSC 241240) has been cited by 69 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[6]
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVKyMVI26oDLzszN MlHnO|IhcA>? NWm0PWxscW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|N{GwOUc,OjZzM{exNFU9N2F-
Tca8113/CBP  NVTz[|ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\BZlIuOjYkgJpOwG0> NXTmPG55PzJiaB?= M17SPYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|N{GwOUc,OjZzM{exNFU9N2F-
Tca8113/PYM  MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1GxVlIuOjYkgJpOwG0> NV;4SGJyPzJiaB?= NGrnUI9qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NI\lWm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO|ExPSd-Mk[xN|cyODV:L3G+
SKOV3 MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDlOYN[PjBibXevcYw> NI\1Z3UyNTViZB?= Mmr2bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlidHnt[UBl\XCnbnTlcpRtgQ>? NXvybI8xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|cxPDNpPkK2NVM4ODR|PD;hQi=>
SKOV3 NEW1V5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3voVFAuPCEQvHevcYw> M4nlfVI1NzR6L{eyJIg> MoXUbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? NX3KR5VbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlUzPzNpPkK2NVI2Ojd|PD;hQi=>
SKOV3 MYfBdI9xfG:|aYOgRZN{[Xl? NX20TZNNOiEQvHevcYw> NXPNZ5NCPDhiaB?= M3LWRolv\HWlZYOgZZBweHSxc3nz MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NUK3N{c,OjZzMkWyO|M9N2F-
OSA MXrDcI9vd2enbnnjJGF{e2G7 MmPnNk42NzVizszN NF71PXVz\XO3bITzJIlvKGyxd3XyJINwdG:weTDmc5Ju[XSrb36gZZMh[2:vcHHy[YQhfG9iZXn0bIVzKEKPSUGgd4lTVkFidILlZZRu\W62 MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzME[yNEc,OjZzMUC2NlA9N2F-
A549 NX;HeGZlTnWldHnvckBCe3OjeR?= Ml3GNE8zPS93MDFOwG0> MofyNlQhcA>? Mkjk[I94dnKnZ4XsZZRmeyCvaWKtNlA2KGW6cILld5Nqd28EoB?= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975 MlP1SpVkfGmxbjDBd5NigQ>? MmTGNE8zPS93MDFOwG0> MkS3NlQhcA>? NWDrU|Z4\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=> NXntR3NvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVc{OTdpPkK1PVE4OzF5PD;hQi=>
A549 NUiyUHgzTnWldHnvckBCe3OjeR?= Ml;1NE8zPS93MDFOwG0> M4\kdVI1KGh? NEn0cZJ2eHKnZ4XsZZRmeyCvaWKtNlE5KGW6cILld5Nqd25? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975 M3vJO2Z2[3Srb36gRZN{[Xl? NWnXb2FpOC9{NT:1NEDPxE1? NGTHZm0zPCCq NWTOSmZTfXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w MlH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N|E4RC:jPh?=
A549 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nmOFI2KM7:TR?= NEPVZ2kzPCCq MmrrbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NYfYN2hIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVc{OTdpPkK1PVE4OzF5PD;hQi=>
H1975 MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXUUVZXOjVizszN MnfNNlQhcA>? NV7mdmx5cW6qaXLpeJMh[2WubDDndo94fGh? MnHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N|E4RC:jPh?=
MDA-MB-231 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHpT2MxNTJ{MDFOwIcwdWx? Ml\2O|IhcA>? MlfzTWM2OMLiPTC4OkDPxE1? M2CwR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO3OlkyLz5{NUizO|Y6OTxxYU6=
T47D NF\1U5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTISGZ6OC1{MkCg{txoN22u MmPBO|IhcA>? NGfXU4JKSzVywrC9JFQ5NjlizszN NEjqSms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizO|Y6OSd-MkW4N|c3QTF:L3G+
LCTCC Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEWyPHlKSzVyPUOuPQKBkcL3TR?= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MCTCC NXHBXYZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:4VWJKSzVyPUKuPQKBkcL3TR?= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MegTCC NVf0UWRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTtTWM2OD12LkJihKnDvU1? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MonoTCC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GzTmlEPTB;NT625qCKyrWP NEi0OoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3N|E3Pyd-MkW3O|MyPjd:L3G+
MCF7 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;BV3RlOjBizszN M4LjPVczKGh? NV2y[nljcW6mdXPld{Bk\WyuIHTlZZRpKG:oIFjQNe6zNWSncHzleIVlKE2FRkegZ4VtdHN? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4OUCyOUc,OjV5NkmwNlU9N2F-
A-549  NIj5UYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HTRVAvPSEQvF2= Mm\uNlQhcA>? M4TzVGROW00EoB?= MWnpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 NGL6OZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1OVY6OCd-MkW3OVU3QTB:L3G+
A-549  NX\NRmNISXCxcITvd4l{KEG|c3H5 MU[wMlUh|ryP Mn3COFghcA>? MYjEUXNQyqB? NI\nUIF{cG:5czDlZZJtgSCjcH;weI9{cXNiZnXheJVz\XNiaX7jcJVlcW6pIHLs[YJjcW6pIHHu[EBkcHKxbXH0bY4h[2:wZHXud4F1cW:w MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NU[5NEc,OjV5NUW2PVA9N2F-
A-549  NEXmW5VHfWO2aX;uJGF{e2G7 MV:wMlUh|ryP NUPaSZd6PDhiaB?= M33kWGROW00EoB?= M3XvRZNpd3e|IHHi[ZJz[W62IH3pZ5JwfHWkdXzlJIRqe3K3cITpc44> NEDZeXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1OVY6OCd-MkW3OVU3QTB:L3G+
A-549  NV:yVYFtTnWldHnvckBCe3OjeR?= MnLDNE42KM7:TR?= M2Hpc|Q5KGh? NVvVWIxpTE2VT9Mg MlXtbY5pcWKrdIOgc4Yh[2WubDDtbYdz[XSrb39CpC=> M4fmTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W1OlkxLz5{NUe1OVY6ODxxYU6=
RMG-1 NUewemM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPUcWljUUN3ME2yPE45KMLzIEOuOkBu\y:O NYHyXIdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlY6OTNpPkK1O|I3QTF|PD;hQi=>
FN-RMG-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTRyLkWgxtEhPC5{IH3nM2wLKM7:TR?= Mm\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mk[5NVMoRjJ3N{K2PVE{RC:jPh?=
RMG-1-hFUT MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHtTGQxUUN3ME21PE4yKMLzIEKuOEBu\y:O NULRUoVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlY6OTNpPkK1O|I3QTF|PD;hQi=>
FN-RMG-1-hFUT Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFzOD64JOKyKDF|LkigcYcwVA>? NXT2b3ZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlY6OTNpPkK1O|I3QTF|PD;hQi=>
CHP-134  MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSxJO69VQ>? MXrEUXNQyqB? MULpcohq[mm2czDzbYdvcW[rY3HueEBk\WyuIHfyc5d1cCClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OES2N{c,OjV4NUi0OlM9N2F-
IMR-32 NIjL[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDMZVFVOSEQvF2= Mo\FSG1UV8Li Mn;obY5pcWKrdIOgd4lodmmoaXPhcpQh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBIW0t{OEOwN|cy MomxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUi0OlMoRjJ3NkW4OFY{RC:jPh?=
CHP-134  MlXuSpVkfGmxbjDBd5NigQ>? NXr0OWdpOTBizszNxsA> MV;EUXNQyqB? NIX5RVVqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? M{DNN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW4OFY{Lz5{NU[1PFQ3OzxxYU6=
IMR-32 MX;GeYN1cW:wIFHzd4F6 NFjKOVgyOCEQvF5CpC=> MkPPSG1UV8Li MnLrbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> MkmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUi0OlMoRjJ3NkW4OFY{RC:jPh?=
A549 M2T4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TyOVAvOi12MECwJO69VQ>? Mm\GO|IhcA>? Mn3ITWM2OD1zMk[gxtEhPS5yIN88US=> Mn[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkWyOFMoRjJ3NkK1NlQ{RC:jPh?=
A549/CDDP MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe2Sm9JOC5{LUSwNFAh|ryP MXy3NkBp NWT1[JA2UUN3ME2yOFDDqMLzwrC0OU44KM7:TR?= NULTeYR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlUzPDNpPkK1OlI2OjR|PD;hQi=>
H460  MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jrXFI1KGh? NGT0bmpFVVOR NYjKZmllUUN3ME23Mlkh|ryP NWHaWlNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVk6QTVpPkK1OVk6QTl3PD;hQi=>
H460  MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHIUJc4NjlizszN MoS1NlQhcA>? NFmzNolFVVOR MlXsd4hwf3NiYTDyZYRqd3OnboPpeIl7cW6pIHXm[oVkfCC2bzDYMZJigXN? NU\u[YlXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVk6QTVpPkK1OVk6QTl3PD;hQi=>
NRK-52E Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLqO|LDqGkEoB?= MoHxTWM2OD1zMECgxtEhOTJwOTFOwG0> NVTXUpo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlU3ODNpPkK1OVY2PjB|PD;hQi=>
RGE MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7SdY1PPzMEoHlCpC=> M3jreWlEPTB;MkKgxtEhPy52IN88US=> NXnpbWtuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlU3ODNpPkK1OVY2PjB|PD;hQi=>
NRK-52E MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PKVVczyqCqwrC= M17sUmlEQDB;MUe5JOKyKDlwNTFOwG0> MlTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkW2NFMoRjJ3NU[1OlA{RC:jPh?=
RGE NW\pfYJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofWO|LDqGkEoB?= M1XUfGlEQDB;NkOgxtEhPy52IN88US=> MmO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkW2NFMoRjJ3NU[1OlA{RC:jPh?=
SK-OV-3 NWe5bINuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ezPVczKGh? NYG1VXJPUUN3ME2xNFQvQCEQvF2= MlnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkCxN|IoRjJ3NUKwNVMzRC:jPh?=
ES-2 NXTsdZdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTQWVI4OiCq MlvYTWM2OD1zND62JO69VQ>? MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN|I9N2F-
OVCAR-8 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XtWlczKGh? MkjSTWM2OD17Nj6wJO69VQ>? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN|I9N2F-
3AO Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDqeYVIPzJiaB?= NVLVZXl3UUN3ME22N{41KM7:TR?= NHn1RlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyNFE{Oid-MkW1NlAyOzJ:L3G+
A2780 NGXTWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jNcVczKGh? M3jIWWlEPTB;MUS1Mlch|ryP MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN|I9N2F-
SW626 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1i4bVczKGh? NHy5UXhKSzVyPUm3MlAh|ryP M{G0fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUKwNVMzLz5{NUWyNFE{OjxxYU6=
OVCAR-3 M3T5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\kS|czKGh? NEjpeJZKSzVyPUOyMlYh|ryP MnTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkCxN|IoRjJ3NUKwNVMzRC:jPh?=
A549 M3u3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H6[WlEPTB;MUWxMlU3KMLzIEWzMlA3KM7:TR?= NF;3SoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Q3OSd-MkWyO|c1PjF:L3G+
4T1 NFnVdWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzVPIlGUUN3ME24OE43OiEEsTCzNE4xPSEQvF2KJO69VQ>? NITYWGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Q3OSd-MkWyO|c1PjF:L3G+
BALB/3T3 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\iTWM2OD1zND6zNEDDuSB4Lk[4JO69VQ>? MlXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
B16 MoDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXWTWM2OD14ND6zNEDDuSB4LkixJO69VQ>? MoWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
DU 145 NX3TR4ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u0bWlEPTB;M{WuNFQhyrFiMUeuOVQh|ryP NWDQXVMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
FaDu MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fUdmlEPTB;NEWuN|khyrFiMUGuOVAh|ryP M2TxU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O|Q3OTxxYU6=
HCV-29T NWT3eXhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4CzdmlEPTB;NEiuOVchyrFiMkKuOFkh|ryP MoDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
HL-60 Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFzLkGwJOKyKDRwNEeg{txO M1nWfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O|Q3OTxxYU6=
HT-29 NVe2b4pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDPT3JKSzVyPUi5MlE3KMLzIEG4Mlg3KM7:TR?= NIK2enc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Q3OSd-MkWyO|c1PjF:L3G+
H146 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f6R2lEPTB;NEmuOuKyOTNwMTFOwG0> MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H187 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO4NmVKSzVyPUGyMlfDuTJwNzFOwG0> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H128 NVjmWWZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrrTWM2OD1zME[uOOKyQS54IN88US=> NHnqS2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
H69 NWP5WXJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjTOmFKSzVyPUe2MlnDuTJ5Lkig{txO MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H209 NH7seJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL6[4czUUN3ME2yOVgvOcLzOUmuPEDPxE1? NVvrOYMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
DMS153 MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrITWM2OD13Nz64xtE6NjJizszN NUTQ[lNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
H526 M1PQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e0emlEPTB;Nz6yxtEyNjdizszN MnLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
DMS114 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjSTWM2OD16NT64xtEyOi56IN88US=> NWrqUndQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
DMS53 M{DIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j6U2lEPTB;MUS2MlLDuTN4LkSg{txO Mn;aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
HeLa MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fDWFUuQDBizszN M2i1NolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MmTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzOlAoRjJ3MUC5N|YxRC:jPh?=
MCF-7 NIqz[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDkOFI2NThyIN88US=> M1KzRolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NFuzc3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVM3OCd-MkWxNFk{PjB:L3G+
MDA-MB-231 NUXaTJZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[0VGg2NThyIN88US=> NYLmfG5zcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyOUO2NEc,OjVzMEmzOlA9N2F-
CaOV3 NFnCW|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVK3NkBp M3fVR2lEPTB;OE[uNUDPxE1? MorzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNki4OFkoRjJ3ME[4PFQ6RC:jPh?=
OVCAR-3 M{X2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rTZ|czKGh? NFO3V45KSzVyPUG3PU42KM7:TR?= M3[xSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
OVCAR-5 M3zTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYq3NkBp M2mxUWlEPTB;N{WuO{DPxE1? NFPrNpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
SKOV-3 NYfi[lN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUe3NkBp MmjvTWM2OD13MESg{txO NFO1bms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
OVCAR-4 NUfNSHp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzTXlJEPzJiaB?= MnzzTWM2OD1{OUCuOkDPxE1? NFTaU209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
OVCAR-8 NFLJR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDwO|IhcA>? NV7XNmh3UUN3ME22PVAvOiEQvF2= NF\1Zos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
MA148 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGyNlQhcA>? MnfZTWM2OD16Mz625qCKyrIkgJmxMlQh|rypL33s MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
A549 M3rPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHoSXEzPCCq NGHiVXlKSzVyPUe3Ok4x6oDLwsJihKkyNjlizsznM41t M4LjdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MDA-MB-231 NGfLcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm1bWQzPCCq NIrWcIpKSzVyPUe0PE4x6oDLwsJihKkyNjFizsznM41t NWn5OWtwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
NCI-ADR/RES  NXrTRnRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXmV5ZCOjRiaB?= MW\JR|UxRTF5NUOuNQKBkcLz4pEJOE41KM7:Zz;tcC=> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
MA148 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnEOFghcA>? Ml[2TWM2OD1{OD6x5qCKyrIkgJmxMlAh|rypL33s MmPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
A549 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\nUHBHPDhiaB?= MkGxTWM2OD1zMUiuNQKBkcLz4pEJNU4zKM7:Zz;tcC=> NWnyN4RZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
MDA-MB-231 MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\DelQ5KGh? NEnaSWlKSzVyPUG4N{4x6oDLwsJihKkyNjJiIN88[{9udA>? NXHxUXFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
NCI-ADR/RES  M2rheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrPOFghcA>? NIjjU2FKSzVyPUG5N{4x6oDLwsJihKkyNjlizsznM41t NXv1[FRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
MA148 M2n1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLUTnI4OiCq NF;iemVKSzVyPUGzMlfjiIoEsfMAjVEvOiEQvHevcYw> NGqzUHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
A549 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfp[2t3PzJiaB?= NWT2SlZoUUN3ME22OE4{6oDLwsJihKkyNjFizsznM41t NYnSb4U5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
MDA-MB-231 M2ewZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P5SFczKGh? NIjRWI5KSzVyPUm5MlXjiIoEsfMAjVEvOSEQvHevcYw> MmHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
NCI-ADR/RES  NYrxemVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG3NkBp NIfE[|RKSzVyPUO3MlTjiIoEsfMAjVEvPyEQvHevcYw> NU\PfIt2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
A549 NEn1RnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnRUJg4OiCq MYrEUXNQ MofOTWM2OD1zNUKuOFA6KM7:TR?= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{MUOyN{c,OjR5MkGzNlM9N2F-
NCI-H157 NWSwbVRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;tO|IhcA>? MlzKSG1UVw>? MmX6TWM2OD16OT65O|ch|ryP MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{MUOyN{c,OjR5MkGzNlM9N2F-
PC9 MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrmR4Q4OiCq Mlj5S2M2OD15MT62xtE6NjViwsXN NYrDW2d3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVg5ODlpPkK0OlE5QDB7PD;hQi=>
A549  Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3jfWROPzJiaB?= M2fRSGdEPTB;MUO2xtE{OS54INM1UeKh M4nNXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkG4PFA6Lz5{NE[xPFgxQTxxYU6=
PC9 M3fWZWFxd3C2b4Ppd{BCe3OjeR?= M4rmfFExOCEEtV2= MlO5O|IhcA>? NV[0VnNkcW6mdXPld{BieG:ydH;zbZM> M1fLXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkG4PFA6Lz5{NE[xPFgxQTxxYU6=
A549  MmPlRZBweHSxc3nzJGF{e2G7 NVfGUoUxOTByINM1US=> M4C1b|czKGh? M4ezfolv\HWlZYOgZZBweHSxc3nz M2rITFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkG4PFA6Lz5{NE[xPFgxQTxxYU6=
A549 M3zocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvyW4czPCCq M1y2WGlEOTB;MT60O|Yhdk1? NWWzbIxpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N|k3PDN5PD;hQi=>
H1299 NHLQOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrG[nAzPCCq NH73eopKSzFyPUCuOFQ{KG6P M1PvOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m2OFM4Lz5{NEO5OlQ{PzxxYU6=
HCC15 NXm1UoJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PEeVI1KGh? NX\rcZFoUUNzME2wMlM1PiCwTR?= NHHlUIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO5OlQ{Pyd-MkSzPVY1Ozd:L3G+
H157 NXf2XIxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHqToszPCCq NUnTO3B4UUNzME2wMlgyKG6P NXrBdpEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N|k3PDN5PD;hQi=>
A2780 M2\QR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP0TWM2OD1zND6w5qCKyrIkgJmxMlQh|ryP M4fSTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkC5Olk{Lz5{NEKwPVY6OzxxYU6=
A2780cisR M2LuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DRV2lEPTB;NEiuPgKBkcLz4pEJN{46KM7:TR?= M4H0T|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkC5Olk{Lz5{NEKwPVY6OzxxYU6=
A2780ZD0473R M{XWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTZ2LkdihKnDueLCiUOuNkDPxE1? NGHjN|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKwPVY6Oyd-MkSyNFk3QTN:L3G+
SKOV-3 NITGfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXFTWM2OD12Mz605qCKyrIkgJmzMlkh|ryP NVjkV21qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNFk3QTNpPkK0NlA6Pjl|PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pChK-2 / Chk-2 ; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p38 / p38 / Cleaved PARP / PARP ; 

PubMed: 30049957     


A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋€𢡄�෋€䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemセ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒セ᎒�堞ﻮ᎒፲露𢡄

30049957
Immunofluorescence
γH2AX ; 

PubMed: 24348048     


Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ

24348048
Growth inhibition assay
Cell viability ; 

PubMed: 24348048     


SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay. 

24348048
In vivo

In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Dosages: ≤60 mg/kg (When Carboplatin is dissolved in sodium chloride solution, it will induce physio-chemical and pharmacokinetic changes.)
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage 2 years 4°C(in the dark) powder
Synonyms JM-8, CBDCA
Smiles C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04606914 Not yet recruiting Drug: mirvetuximab soravtansine (MIRV; IMGN853) Ovarian Cancer|Fallopian Tube|Primary Peritoneal Cancer University of Alabama at Birmingham March 31 2021 Phase 2
NCT04865250 Recruiting Drug: Atezolizumab NSCLC Stage II|NSCLC Stage IIIA|NSCLC Stage IIIB University Hospital Heidelberg|Roche Pharma AG January 7 2021 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

Tags: buy Carboplatin (NSC 241240) | Carboplatin (NSC 241240) supplier | purchase Carboplatin (NSC 241240) | Carboplatin (NSC 241240) cost | Carboplatin (NSC 241240) manufacturer | order Carboplatin (NSC 241240) | Carboplatin (NSC 241240) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID